Bird Flu > Bird Flu News > Can-Fite's CF102 decreases HCV viral load in liver cancer patients

Can-Fite's CF102 decreases HCV viral load in liver cancer patients
Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange reported today that a significant decrease in HCV viral load was detected in 3 patients with liver cancer who are treated daily orally with CF102. The company is studying CF102 as a treatment for liver cancer (hepatocellular carcinoma, or HCC). The results announced today relate to data which came out of a ...